Extensively drug-resistant tuberculosis (XDR-TB)
A course of treatment for uncomplicated tuberculosis takes a minimum of six months. When patients are resistant to the two most powerful first-line antibiotics (isoniazid and rifampicin), they are considered to have multidrug-resistant TB (MDR-TB).
Extensively drug-resistant tuberculosis (XDR-TB) is identified when patients show resistance to the second-line drugs administered for MDR-TB. The treatment options for XDR-TB are very limited. Two new drugs – bedaquiline and delamanid – have recently become available to some patients who have no other treatment options left.
For more information, please see tuberculosis.
- Access to essential medicineApply Access to essential medicine filter (24)
- Access to healthcareApply Access to healthcare filter (8)
- Antibiotic resistanceApply Antibiotic resistance filter (4)
- Child healthApply Child health filter (2)
- Health policyApply Health policy filter (2)
- Mental healthApply Mental health filter (2)
- MigrantApply Migrant filter (1)
- Refugees and internally displaced peopleApply Refugees and internally displaced people filter (1)
- Extensively drug-resistant tuberculosis (XDR-TB)Apply Extensively drug-resistant tuberculosis (XDR-TB) filter (42)
- Hepatitis CApply Hepatitis C filter (1)
- HIV/AIDSApply HIV/AIDS filter (3)
- Infectious diseasesApply Infectious diseases filter (42)
- Multidrug-resistant tuberculosis (MDR-TB)Apply Multidrug-resistant tuberculosis (MDR-TB) filter (42)
- TuberculosisApply Tuberculosis filter (42)